156 related articles for article (PubMed ID: 18806727)
1. Pharmacokinetic principles of immunosuppressive drugs.
Budde K; Glander P
Ann Transplant; 2008; 13(3):5-10. PubMed ID: 18806727
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications.
Weimert NA; Derotte M; Alloway RR; Woodle ES; Vinks AA
Ther Drug Monit; 2007 Apr; 29(2):141-9. PubMed ID: 17417067
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring in cancer--are we missing a trick?
Bardin C; Veal G; Paci A; Chatelut E; Astier A; Levêque D; Widmer N; Beijnen J
Eur J Cancer; 2014 Aug; 50(12):2005-9. PubMed ID: 24878063
[TBL] [Abstract][Full Text] [Related]
4. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
[TBL] [Abstract][Full Text] [Related]
5. Prospects for personalized immunosuppression: pharmacologic tools--a review.
Del Tacca M
Transplant Proc; 2004 Apr; 36(3):687-9. PubMed ID: 15110631
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring in kidney and liver transplantation: current advances and future directions.
Ntobe-Bunkete B; Lemaitre F
Expert Rev Clin Pharmacol; 2024; 17(5-6):505-514. PubMed ID: 38725273
[TBL] [Abstract][Full Text] [Related]
7. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic monitoring of cyclosporine A].
Komzáková I; Safarcík K; Brozmanová H; Grundmann M
Ceska Slov Farm; 2002 Jul; 51(4):159-67. PubMed ID: 12183901
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers as a tool for management of immunosuppression in transplant patients.
Wieland E; Olbricht CJ; Süsal C; Gurragchaa P; Böhler T; Israeli M; Sommerer C; Budde K; Hartmann B; Shipkova M; Oellerich M
Ther Drug Monit; 2010 Oct; 32(5):560-72. PubMed ID: 20814352
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic monitoring: analytic, pharmacokinetic and clinical aspects].
Marquet P
Acta Clin Belg; 1999; 53 Suppl 1():2-12. PubMed ID: 10216973
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells.
Lemaitre F; Blanchet B; Latournerie M; Antignac M; Houssel-Debry P; Verdier MC; Dermu M; Camus C; Le Priol J; Roussel M; Zheng Y; Fillatre P; Curis E; Bellissant E; Boudjema K; Fernandez C
Clin Biochem; 2015 Apr; 48(6):406-11. PubMed ID: 25562187
[TBL] [Abstract][Full Text] [Related]
12. Drug target molecules to guide immunosuppression.
Bergan S; Bremer S; Vethe NT
Clin Biochem; 2016 Mar; 49(4-5):411-8. PubMed ID: 26453533
[TBL] [Abstract][Full Text] [Related]
13. Evolution of the therapeutic drug monitoring of cyclosporine.
Citterio F
Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study.
Steinebrunner N; Sandig C; Sommerer C; Hinz U; Giese T; Stremmel W; Zahn A
Ann Transplant; 2014 Jan; 19():32-40. PubMed ID: 24457606
[TBL] [Abstract][Full Text] [Related]
15. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.
Wallemacq P; Armstrong VW; Brunet M; Haufroid V; Holt DW; Johnston A; Kuypers D; Le Meur Y; Marquet P; Oellerich M; Thervet E; Toenshoff B; Undre N; Weber LT; Westley IS; Mourad M
Ther Drug Monit; 2009 Apr; 31(2):139-52. PubMed ID: 19177031
[TBL] [Abstract][Full Text] [Related]
16. Protease inhibitor plasma concentrations in HIV antiretroviral therapy.
Justesen US
Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158
[TBL] [Abstract][Full Text] [Related]
17. Opportunity to monitor immunosuppressive drugs in peripheral blood mononuclear cells: where are we and where are we going?
Lemaitre F; Antignac M; Verdier MC; Bellissant E; Fernandez C
Pharmacol Res; 2013 Aug; 74():109-12. PubMed ID: 23792083
[TBL] [Abstract][Full Text] [Related]
18. Point-of-Care Therapeutic Drug Monitoring for Precision Dosing of Immunosuppressive Drugs.
Taddeo A; Prim D; Bojescu ED; Segura JM; Pfeifer ME
J Appl Lab Med; 2020 Jul; 5(4):738-761. PubMed ID: 32533157
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring of cyclosporine.
Midtvedt K
Transplant Proc; 2004 Mar; 36(2 Suppl):430S-433S. PubMed ID: 15041380
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometry-based pharmacodynamic monitoring after organ transplantation.
Dieterlen MT; Eberhardt K; Tarnok A; Bittner HB; Barten MJ
Methods Cell Biol; 2011; 103():267-84. PubMed ID: 21722807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
